AXSM
Axsome Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$155.81
−0.85%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$157.54
From 52W high−38.94%
Volume769916.00
Market cap$8.16B
P/E (TTM)—
P/S (TTM)10.5x
Div yield—
Key dataOct 19, 2026
Open
$157.54
From 52W high
−38.94%
Volume
769916.00
Market cap
$8.16B
ValuationView details →
P/E (Fwd)
114.3x
EV/EBITDA
−45.8x
P/E (TTM)
—
RSI (14)
23.9
MomentumView details →
1D Return
−0.85%
YTD Return
−14.01%
SummaryUpdated Jun 1, 2026
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical company founded in 2012 and headquartered in New York. The company went public in 2015 and focuses on developing and commercializing novel therapies for central nervous system (CNS) disorders. Axsome has successfully transitioned from a pure development-stage company to a commercial-stage biopharmaceutical company with multiple approved products generating significant revenue growth.
Similar companies
Latest newsMore news →
Axsome Therapeutics announced that it will report its third-quarter 2026 financial results on November 2, 2026, before U.S. markets open, followed by a management conference call at 8:00 a.m. Eastern Time.12d agoTempest Therapeutics, Inc. appointed Constance Ames as Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary, effective September 22, 2026.21d ago